Abaloparatide is a PTHrP analog. It is filed in this library under bones & muscles, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Abaloparatide has an FDA-approved product on the U.S. market, marketed as Tymlos under application NDA208743.
The current label is held by Radius Health, Inc.
From the FDA label
is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.Quoted from the FDA-approved prescribing information
The evidence
We could not resolve a published study for Abaloparatide to a verifiable source. That absence is itself worth knowing, and we would rather say so than fill the space.
Nearby
Markers on this pathway
Abaloparatide's FDA-approved label indicates it for a bone or parathyroid condition. These are the markers clinicians use when assessing calcium and bone turnover. They are listed here so you can read about them, not as a statement that Abaloparatide changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Abaloparatide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides